Literature DB >> 17550866

AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism.

Chirayu U Auewarakul, Amporn Leecharendkeat, Chintana Tocharoentanaphol, Orathai Promsuwicha, Narongrit Sritana, Wanna Thongnoppakhun.   

Abstract

AML1 mutations were identified in 6.3% of AML patients with chromosomal translocations involving CBF, PML-RARalpha, HOX, or ETS transcription factor (TF) gene families. Rare chromosomal abnormalities, t(16;21) and t(7;11), were also found. This study represents the first series to demonstrate the coexistence of known and novel AML1 mutations with different TF gene mutations. Although the occurrence of two TF gene mutations may appear unnecessary, the possible synergistic mechanism between different TF gene families cannot be excluded and needs to be further explored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17550866     DOI: 10.3324/haematol.10914

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

1.  RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.

Authors:  AHyun Choi; Anuradha Illendula; John A Pulikkan; Justine E Roderick; Jessica Tesell; Jun Yu; Nicole Hermance; Lihua Julie Zhu; Lucio H Castilla; John H Bushweller; Michelle A Kelliher
Journal:  Blood       Date:  2017-08-08       Impact factor: 22.113

2.  CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22).

Authors:  Dong Wook Jekarl; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Ah-Won Lee; Hee-Je Kim; Woo-Sung Min
Journal:  Int J Hematol       Date:  2010-08-10       Impact factor: 2.490

Review 3.  TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review.

Authors:  Heyang Zhang; Qianru Zhan; Xiaoxue Wang; Feng Gao; Jinxiang Yu; Jing Wang; Wei Fu; Pingping Wang; Xin Wei; Lijun Zhang
Journal:  Ann Hematol       Date:  2022-10-01       Impact factor: 4.030

4.  RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).

Authors:  Olfat Ismael; Akira Shimada; Shaimaa Elmahdi; Momen Elshazley; Hideki Muramatsu; Asahito Hama; Yoshiyuki Takahashi; Miho Yamada; Yuka Yamashita; Keizo Horide; Seiji Kojima
Journal:  Int J Hematol       Date:  2013-12-28       Impact factor: 2.490

5.  Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.

Authors:  Takatoshi Aoki; Toshihiro Miyamoto; Shuro Yoshida; Asataro Yamamoto; Takuji Yamauchi; Goichi Yoshimoto; Yasuo Mori; Kenjiro Kamezaki; Hiromi Iwasaki; Katsuto Takenaka; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2008-11-13       Impact factor: 2.490

6.  Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.

Authors:  Giusy Della Gatta; Teresa Palomero; Arianne Perez-Garcia; Alberto Ambesi-Impiombato; Mukesh Bansal; Zachary W Carpenter; Kim De Keersmaecker; Xavier Sole; Luyao Xu; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Jules P Meijerink; Andrea Califano; Adolfo A Ferrando
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

7.  Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Authors:  Sadudee Chotirat; Wanna Thongnoppakhun; Orathai Promsuwicha; Chetsada Boonthimat; Chirayu U Auewarakul
Journal:  J Hematol Oncol       Date:  2012-03-07       Impact factor: 23.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.